ArticleCritical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine2026
A prospective, multi-site, observational study assessing the treatment thresholds of new onset atrial fibrillation in the critically ill.
Article in Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To define haemodynamic thresholds for pharmacological treatment of new-onset atrial fibrillation (NOAF) in critically ill patients and examine associations with short-term outcomes including reversion to sinus rhythm and in-hospital mortality. Design setting and participants: prospective multicentre observational cohort study conducted across six Australian intensive care units (ICUs) from December 2024 to September 2025. Adult patients (≥18 years) who developed NOAF during ICU admission were included. A Cox proportional hazards model treating time to treatment as a time-dependent covariate was used to assess associations between pharmacological therapy and secondary outcomes. Main outcome measures: The primary outcome was heart rate at initiation of the first pharmacological therapy for NOAF. Secondary outcomes included mean arterial pressure at time of treatment, reversion to sinus rhythm, haemodynamic deterioration, ICU length of stay, and in-hospital mortality. Results: Four hundred eighty-two patients were screened for eligibility and 210 met the inclusion criteria. One hundred fifty-four (73.3%) received pharmacological treatment for NOAF. The median heart rate at treatment initiation was 128 beats per minute (interquartile range [IQR]: 113-147) and median mean arterial pressure 76 mmHg (IQR: 70-87). Pharmacological treatment was not independently associated with sustained reversion to sinus rhythm (adjusted hazard ratio: 1.44, 95% confidence interval [CI]: 0.94-2.20) or in-hospital mortality (adjusted odds ratio: 0.96, 95% CI: 0.36-2.58). Pharmacological treatment was associated with prolonged ICU stay (multiplicative adjusted effect: 1.39, 95% CI: 1.06-1.82). Conclusions: Pharmacological treatment for NOAF is typically initiated at heart rates approximating 130 bpm. After accounting for time-dependent exposure, pharmacological treatment was not independently associated with reversion to sustained sinus rhythm. Given the methodological limitations encountered, these findings warrant validation in randomised trials to better define optimal treatment strategies for NOAF in critical illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.